ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+10.92%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$6.36B
AUM Growth
+$6.36B
(+11%)
Cap. Flow
+$136M
Cap. Flow
% of AUM
2.14%
Top 10 Holdings %
Top 10 Hldgs %
71.18%
Holding
48
New
4
Increased
11
Reduced
10
Closed
5
Top Buys
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$172M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$132M |
| 3 |
Amicus Therapeutics
FOLD
|
$49.9M |
| 4 |
PMV Pharmaceuticals
PMVP
|
$32.8M |
| 5 |
Kymera Therapeutics
KYMR
|
$26.8M |
Top Sells
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$108M |
| 2 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$78.4M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$38.7M |
| 4 |
Relmada Therapeutics
RLMD
|
$29.9M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$28.3M |
Sector Composition
| 1 | Healthcare | 97.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $986M | 15.49% | 9,000,000 | – | – |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $885M | 13.89% | 5,000,000 | – | – |
|
|
XLRN
3
DELISTED
Acceleron Pharma Inc.
XLRN
| $688M | 10.81% | 4,000,000 +1,000,000 | +33% | +$172M |
|
4
United Therapeutics
UTHR
$13.8B
| $554M | 8.7% | 3,000,000 | – | – |
|
5
Ascendis Pharma
ASND
$11.8B
| $316M | 4.96% | 1,980,000 +80,000 | +4% | +$12.8M |
|
6
argenx
ARGX
$43.6B
| $286M | 4.49% | 946,500 | – | – |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $231M | 3.63% | 2,500,000 +100,000 | +4% | +$9.25M |
|
8
Iovance Biotherapeutics
IOVA
$807M
| $210M | 3.29% | 8,500,000 -600,000 | -7% | -$14.8M |
|
|
ARNA
9
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $204M | 3.2% | 3,425,000 -650,000 | -16% | -$38.7M |
|
|
10
Amicus Therapeutics
FOLD
$2.34B
| $169M | 2.65% | 17,679,273 +5,229,273 | +42% | +$49.9M |
|
|
11
Apellis Pharmaceuticals
APLS
$3.48B
| $165M | 2.59% | 5,000,000 +3,994,770 | +397% | +$132M |
|
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $160M | 2.52% | 850,000 -150,000 | -15% | -$28.3M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $145M | 2.28% | 1,875,000 +225,000 | +14% | +$17.4M |
|
14
Vertex Pharmaceuticals
VRTX
$100B
| $120M | 1.89% | 664,000 -126,000 | -16% | -$22.9M |
|
|
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $115M | 1.81% | 7,100,000 +675,000 | +11% | +$11M |
|
16
Madrigal Pharmaceuticals
MDGL
$9.76B
| $114M | 1.79% | 1,425,000 | – | – |
|
|
TRIL
17
DELISTED
Trillium Therapeutics Inc.
TRIL
| $100M | 1.57% | 5,700,000 | – | – |
|
|
18
PMV Pharmaceuticals
PMVP
$74.2M
| $87.2M | 1.37% | 2,925,000 +1,100,000 | +60% | +$32.8M |
|
19
Kura Oncology
KURA
$686M
| $74.9M | 1.18% | 4,000,000 -140,000 | -3% | -$2.62M |
|
20
Mersana Therapeutics
MRSN
$36.5M
| $64.1M | 1.01% | 6,800,000 | – | – |
|
21
Monte Rosa Therapeutics
GLUE
$296M
| $61M | 0.96% | 3,311,434 | – | – |
|
22
Xenon Pharmaceuticals
XENE
$2.98B
| $55.8M | 0.88% | 3,650,000 | – | – |
|
|
WHWK
23
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $53.7M | 0.84% | 1,829,402 -2,670,598 | -59% | -$78.4M |
|
24
MannKind Corp
MNKD
$1.41B
| $38.3M | 0.6% | 8,800,000 +170,000 | +2% | +$740K |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $37.6M | 0.59% | 10,300,000 | – | – |
|